>>17489454

>>17489468

https://en.wikipedia.org/wiki/The_Manchurian_Candidate

The Manchurian Candidate is a novel by Richard Condon, first published in 1959.It is a political thriller about the son of a prominent U.S. political family who is brainwashed into being an unwitting assassin for a Communist conspiracy.

The novel has twice been adapted into a feature film with the same title: the first was released in 1962 and the second in 2004.

Plot summary

Major Bennett Marco, Sergeant Raymond Shaw, and the rest of their infantry platoon are captured by an elite Soviet commando unit during the Korean War in 1952. They are taken to Manchuria, and brainwashed into believing Shaw saved their lives in combat – for which Shaw is subsequently awarded the Medal of Honor.

Years after the war, Marco, now back in the United States working as an intelligence officer, begins suffering a recurring nightmare in which the seated platoon members are surrounded by a group of sweet little old ladies who had been a part of their brainwashing. One of the ladies tells Sergeant Shaw to murder two of his platoon comrades. The backdrop with the old ladies changes back and forth between them and Chinese/Soviet intelligence officials. When Marco learns that another of the platoon's soldiers has been suffering the exact same nightmare, he starts looking into why this is happening.

Major Marco looks up Sergeant Raymond Shaw and discovers that Shaw's new manservant is someone he recognizes from Korea. Marco and the manservant start fighting in Shaw's house and both are bloodied significantly. Marco is arrested, and when Shaw sees that it is his old major they rekindle their old friendship. Both find love interests: for Marco, it is Rose Cheyney, whom he meets on a train; and for Raymond, it is Jocelyn Jordan, the daughter of Senator Thomas Jordan, a neighbor of Shaw's. Senator Jordan and Shaw's mother do not like each other, but Raymond continues to see Jocelyn.

It is revealed that the Communists have been using Shaw as a sleeper agent who, activated by a post-hypnotic trigger, immediately forgets the assignments he carries out and therefore can never betray the operation either purposely or inadvertently. In Shaw's case, the suggestion that he play solitaire is the trigger. Seeing the queen of diamonds playing card transforms him into an assassin who will kill anyone at whom he is directed. Shaw's KGB handler is his domineering mother, Eleanor. Married to McCarthy-esque Senator Johnny Iselin, Eleanor has convinced the Communist powers to help install her husband as president and allow them to control the American government through him.

By observing Shaw, Marco discovers the trigger shortly before the national convention of Iselin's political party. He uses the queen of diamonds card to draw out Eleanor's plan: after she obtains the vice presidential nomination for Iselin, Shaw is to shoot the presidential candidate so that Iselin can succeed him. Blaming the killing on the Communists will enable Iselin to assume dictatorial powers. Marco reprograms Shaw, although it is unclear until the final pages whether this is successful. At the convention, Shaw instead shoots and kills his mother and Senator Iselin. Marco is the first person to reach Shaw's sniper nest, getting there just before Shaw turns the gun on himself and commits suicide.

1/

>>17489532

Alleged plagiarism

In 1998, software developer C. J. Silverio noted that several long passages of the novel seemed to be adapted from Robert Graves's 1934 novel I, Claudius…

Film adaptations

The book has twice been adapted into a feature film of the same title. The Manchurian Candidate (1962) is considered a classic of the political thriller genre.[5] It was directed by John Frankenheimer and starred Laurence Harvey as Shaw, Frank Sinatra as Marco, and Angela Lansbury as Eleanor in an Academy Award-nominated performance.

The Manchurian Candidate (2004) was directed by Jonathan Demme and starred Liev Schreiber as Shaw, Denzel Washington as Marco, and Meryl Streep as Eleanor. It was generally well received by critics, and moderately successful at the box office. The film updated the conflict (and brainwashing) to the Persian Gulf War in 1991, had a U.S. corporation (called "Manchurian Global") as the perpetrator of the brainwashing and conspiracy instead of foreign Communist groups, and dropped the Johnny Iselin character in favor of making both Shaw and his mother elected politicians.

Both adaptations discard several elements of the book. The book spends more time describing the brainwashers and the facility in Manchuria where the Americans were held. The head of the project grants Raymond a "gift"; after his brainwashing, he becomes quite sexually active, in contrast to his reserved nature beforehand when he had not even kissed his love interest, Jocelyn Jordan.

In the novel, Mrs. Iselin and her son travel abroad, where she uses him to kill various political figures and possibly Jocelyn Jordan's first husband. Rosie, Marco's love interest, is the ex-fiancée of one of his associates handling the Shaw case for Army Intelligence, making things between the couple tense. The movie adaptations also all but omit the novel's portrayal of incest between Raymond and his mother, only hinting at it with a mouth-to-mouth kiss.

As a child, Mrs. Iselin was sexually abused by her father, but fell in love with him and idolized him after his early death. Towards the end of the book, as Raymond is hypnotized by the Queen of Diamonds, he reminds her of her father and they sleep together.

The 1962 version does not state outright the political affiliation of Senators Iselin and Jordan (implied to be Republicans), although in the 2004 film the equivalent characters are Democrats. According to David Willis McCullough, Senator Iselin is modeled on Republican senator Joseph McCarthy and, according to Condon, Shaw's mother is based on McCarthy's counsel Roy Cohn.

2/

>>17489572

bullshit alibi

they were ordered to do what they did by the same powers being exposed by the research being conducted by the 8chan users.

Open-source research is discussed and annotated as to source. This is what was unacceptable to their hold on power.

Ivermectin was a dirty word yesterday and users were cast into digital purgatory. Today it is Science.

>>17489597

>Ivermectin

https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19

Why You Should Not Use Ivermectin to Treat or Prevent COVID-19

fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19

COVID-19. We’ve been living with it for what sometimes seems like forever. Given the number of deaths that have occurred from the disease, it’s perhaps not surprising that some consumers are turning to drugs not approved or authorized by the Food and Drug Administration (FDA).

One of the FDA’s jobs is to carefully evaluate the scientific data on a drug to be sure that it is both safe and effective for a particular use. In some instances, it can be highly dangerous to use a medicine for the prevention or treatment of COVID-19 that has not been approved by or has not received emergency use authorization from the FDA.

There seems to be a growing interest in a drug called ivermectin for the prevention or treatment of COVID-19 in humans. Certain animal formulations of ivermectin such as pour-on, injectable, paste, and "drench," are approved in the U.S. to treat or prevent parasites in animals. For humans, ivermectin tablets are approved at very specific doses to treat some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea.

However, the FDA has received multiple reports of patients who have required medical attention, including hospitalization, after self-medicating with ivermectin intended for livestock.

Here’s What You Need to Know about Ivermectin

The FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals. Ivermectin is approved for human use to treat infections caused by some parasitic worms and head lice and skin conditions like rosacea.

Currently available data do not show ivermectin is effective against COVID-19. Clinical trials assessing ivermectin tablets for the prevention or treatment of COVID-19 in people are ongoing.

Taking large doses of ivermectin is dangerous.

If your health care provider writes you an ivermectin prescription, fill it through a legitimate source such as a pharmacy, and take it exactly as prescribed.

Never use medications intended for animals on yourself or other people. Animal ivermectin products are very different from those approved for humans. Use of animal ivermectin for the prevention or treatment of COVID-19 in humans is dangerous.

What is Ivermectin and How is it Used?

Ivermectin tablets are approved by the FDA to treat people with intestinal strongyloidiasis and onchocerciasis, two conditions caused by parasitic worms. In addition, some topical forms of ivermectin are approved to treat external parasites like head lice and for skin conditions such as rosacea.

Some forms of animal ivermectin are approved to prevent heartworm disease and treat certain internal and external parasites. It’s important to note that these products are different from the ones for people, and safe only when used in animals as prescribed.

When Can Taking Ivermectin Be Unsafe?

The FDA has not authorized or approved ivermectin for the treatment or prevention of COVID-19 in people or animals. Ivermectin has not been shown to be safe or effective for these indications.

There’s a lot of misinformation around, and you may have heard that it’s okay to take large doses of ivermectin. It is not okay.

Even the levels of ivermectin for approved human uses can interact with other medications, like blood-thinners. You can also overdose on ivermectin, which can cause nausea, vomiting, diarrhea, hypotension (low blood pressure), allergic reactions (itching and hives), dizziness, ataxia (problems with balance), seizures, coma and even death.

>>17489603

>Why You Should Not Use Ivermectin to Treat or Prevent COVID-19

https://www.thepharmaletter.com/article/usa-clears-ivermectin-for-human-use

USA Clears Ivermectin For Human Use

thepharmaletter.com/article/usa-clears-ivermectin-for-human-use

02-12-1996 Print

In the USA, the Food and Drug Administration has approved Merck & Co's Stromectil (ivermectin) for its first non-veterinary use, the chemotherapy of two parasitic infections, strongyloidiasis and onchocerciasis, in humans. Ivermectin has been used in humans in other countries since 1987, and has been used to treat more than 5.2 million people worldwide.

IvermectinMerck KGaAStromectol

https://www.thepharmaletter.com/article/usa-clears-ivermectin-for-human-use

USA Clears Ivermectin For Human Use

thepharmaletter.com/article/usa-clears-ivermectin-for-human-use

In the USA, the Food and Drug Administration has approved Merck & Co's Stromectil (ivermectin) for its first non-veterinary use, the chemotherapy of two parasitic infections, strongyloidiasis and onchocerciasis, in humans. Ivermectin has been used in humans in other countries since 1987, and has been used to treat more than 5.2 million people worldwide.

translation: FDA has received and accepted their necessary $bribes from giants such as pharmaceutical giant ~~Merck ~~Quack and is now approved for use.

the same drug based on the same studies…

>>17489633

>Stromectil

Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects

cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-for-covid-19-led-up-to-a-92-reduction-in-covid-19-mortality-rate-in-a-dose-response-manner-results-of-a-prospective-observational-study-of-a-strictly-controlled-population-of-88012-subjects

Original article

peer-reviewed

Lucy Kerr, Fernando Baldi, Raysildo Lobo, Washington Luiz Assagra, Fernando Carlos Proença, Juan J. Chamie, Jennifer A. Hibberd, Pierre Kory, Flavio A. Cadegiani

Published: August 31, 2022 (see history)

DOI: 10.7759/cureus.28624

Cite this article as: Kerr L, Baldi F, Lobo R, et al. (August 31, 2022) Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects. Cureus 14(8): e28624. doi:10.7759/cureus.28624

Abstract

Background

We have previously demonstrated that ivermectin used as prophylaxis for coronavirus disease 2019 (COVID-19), irrespective of the regularity, in a strictly controlled citywide program in Southern Brazil (Itajaí, Brazil), was associated with reductions in COVID-19 infection, hospitalization, and mortality rates. In this study, our objective was to determine if the regular use of ivermectin impacted the level of protection from COVID-19 and related outcomes, reinforcing the efficacy of ivermectin through the demonstration of a dose-response effect.

Methods

This exploratory analysis of a prospective observational study involved a program that used ivermectin at a dose of 0.2 mg/kg/day for two consecutive days, every 15 days, for 150 days. Regularity definitions were as follows: regular users had 180 mg or more of ivermectin and irregular users had up to 60 mg, in total, throughout the program. Comparisons were made between non-users (subjects who did not use ivermectin), and regular and irregular users after multivariate adjustments. The full city database was used to calculate and compare COVID-19 infection and the risk of dying from COVID-19. The COVID-19 database was used and propensity score matching (PSM) was employed for hospitalization and mortality rates.

Results

Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg). The remaining 71,548 participants were not included in the analysis. COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%) (risk rate (RR): 0.51; 95% CI: 0.45-0.58; p < 0.0001), and 25% lower than irregular users (4.54%) (RR: 0.75; 95% CI: 0.66-0.85; p < 0.0001). The infection rate was 32% lower for irregular users than non-users (RR: 0.68; 95% CI: 0.64-0.73; p < 0.0001). Among COVID-19 participants, regularusers were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users. After PSM, the matched analysis contained 283 subjects in each group of non-users and regular users, between regular users and irregular users, and 1,542 subjects between non-users and irregular users. The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users (RR: 0.781; 95% CI: 0.49-1.05; p = 0.099). Mortality rate was 92% lower in regular users than non-users (RR: 0.08; 95% CI: 0.02-0.35; p = 0.0008) and 84% lower than irregular users (RR: 0.16; 95% CI: 0.04-0.71; p = 0.016), while irregular users had a 37% lower mortality rate reduction than non-users (RR: 0.67; 95% CI: 0.40-0.99; p = 0.049). Risk of dying from COVID-19 was 86% lower among regular users than non-users (RR: 0.14; 95% CI: 0.03-0.57; p = 0.006), and 72% lower than irregular users (RR: 0.28; 95% CI: 0.07-1.18; p = 0.083), while irregular users had a 51% reduction compared to non-users (RR: 0.49; 95% CI: 0.32-0.76; p = 0.001).

Conclusion

Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.

Introduction

>>17489641

>Introduction

Introduction

Ivermectin has been proposed as potential prophylaxis and therapy for coronavirus disease 2019 (COVID-19) due to its previously reported anti-viral [1-4], metabolic [5-10], and anti-inflammatory [11-19] actions, with strong plausibility [20,21] and positive in vitro, in vivo, and epidemiological findings [22-24] in preliminary studies.

Between July and December 2020, a citywide program in Itajaí, in the state of Santa Catarina, Southern Brazil, offered a voluntary, medically prescribed program of ivermectin as prophylaxis for COVID-19. This was based on the extensive, well-established safety profile and known absence of risks with long-term use of ivermectin, and the lack of therapeutic and preventive alternative options in 2020.

The systematically collected data within this program demonstrated that ivermectin used as prophylaxis for COVID-19 improved COVID-19 related-outcomes. The use of ivermectin led to a 44% reduction in infection rate, a 56% reduction in hospitalization rate, and a 68% reduction in mortality rate by using propensity score matching (PSM) to balance the study groups [25].

These conclusions were based on an analog evaluation of the intent-to-treat (ITT) analysis of randomized clinical trials (RCTs). All participants of the program were included for analysis, irrespective of regularity or the total amount of ivermectin taken. Among participants of the ivermectin use (regular and irregular) as prophylaxis for the COVID-19 program, it was unknown if regular ivermectin use would lead to a more substantial reduction in COVID-19 infection rate and related outcomes than irregular use.

In this study, an evaluation was done with participants that used ivermectin prophylactically for COVID-19, to determine if regular use compared to irregular use impacted the degree of reduction in COVID-19 infection, hospitalization, and mortality rates. Regular and irregular ivermectin users were also compared to non-users to evaluate evidence of a dose-response pattern of efficacy.

Materials & Methods

Study population

A thorough description of the program, study population, and protocol was described elsewhere [25]. This was a medically based, observational, and prospective study that involved the voluntary use of ivermectin as prophylaxis for COVID-19 in the city of Itajaí, Santa Catarina, Brazil. It was a citywide program conducted between July 7 and December 2, 2020. Data were collected prospectively and systematically, as was the mandatory reporting of all events.

The study design, institutional review board (IRB) approval, and data analysis were done upon completion of the program. The study of the COVID-19 cases reported in the city of Itajaí (n = 9,956, including cases that occurred before July 7, 2020, as a comparison) was approved by the National Research Ethics Council (CONEP) (approval number: 4.821.082; protocol (CAAE) number: 47124221.2.0000.5485).

Study procedures and data collection

Voluntary prophylactic use of ivermectin was offered as an option to patients during medical visits in a provisional outpatient clinic at the Convention Center and in secondary outpatient clinics at local health centers in the city of Itajaí, as part of the Universal Health System (SUS). During medical visits, patient data, including medical history, comorbidities, previous diseases, medications, and physical signs (body weight, height, body mass index, systolic and diastolic blood pressure, and heart rate), were recorded in the SUS-based system. Ivermectin was then optionally prescribed in a dose of 0.2 mg/kg/day for two consecutive days, every 15 days to participants who presented without symptoms of COVID-19 or any contradictions to ivermectin.

>>17489686

>>17489702

>>17489722

https://youtu.be/L6OmE7_Ngi8

>>17489811